N-acetyl-3-methylhistidine
Also Known As:
L-Histidine, N-acetyl-3-methyl-
Networked: 3
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Arking, Dan E:
1 article
(12/2020)
|
2. | Boerwinkle, Eric:
1 article
(12/2020)
|
3. | Coresh, Josef:
1 article
(12/2020)
|
4. | Grams, Morgan E:
1 article
(12/2020)
|
5. | Hung, Adriana M:
1 article
(12/2020)
|
6. | Köttgen, Anna:
1 article
(12/2020)
|
7. | Luo, Shengyuan:
1 article
(12/2020)
|
8. | Nadkarni, Girish N:
1 article
(12/2020)
|
9. | Rhee, Eugene P:
1 article
(12/2020)
|
10. | Schlosser, Pascal:
1 article
(12/2020)
|
Related Diseases
1. | Renal Insufficiency (Renal Failure)
12/31/2020
- " Higher circulating levels of five of these N-acetylated amino acids, namely, N-δ-acetylornithine, N-acetyl-1-methylhistidine, N-acetyl-3-methylhistidine, N-acetylhistidine, and N2,N5-diacetylornithine, were associated with kidney failure, after adjustment for confounders and combining results in meta-analysis (combined hazard ratios per two-fold higher amino acid levels: 1.48, 1.44, 1.21, 1.65, and 1.41, respectively; 95% confidence intervals: 1.21 to 1.81, 1.22 to 1.70, 1.08 to 1.37, 1.29 to 2.10, and 1.17 to 1.71, respectively; all P values <0.05/14). "
|
2. | Neoplasms (Cancer)
|
3. | Body Weight (Weight, Body)
|
|
Related Drugs and Biologics